(Approval lapsed) Yervoy ipilimumab 50mg/10mL injection (USA)
Section 19A approved medicine
(Approval lapsed) Yervoy ipilimumab 50mg/10mL injection (USA)
Section 19A approval holder
Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322
Phone
1800 067 567
Approved until
Status
Expired
Medicines in short supply/unavailable
YERVOY ipilimumab (rch) 50mg in 10mL (5mg/mL) concentrate solution for IV infusion vial AUST R: 174319
Indication(s)
- Melanoma - YERVOY, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma. YERVOY, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma.
- Renal Cell Carcinoma (RCC) - YERVOY, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.
- Non-Small Cell Lung Cancer (NSCLC) - YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.
- Malignant Pleural Mesothelioma (MPM) - YERVOY, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.